PD Dr. Özlem Türeci

PD Dr. Özlem Türeci

Özlem Türeci has dedicated more than two decades to the discovery of unique drug targets with exceptional cancer-cell selectivity and to the creation of potent immunotherapy drug platforms to enable treatment of patients in an individualized and tailored manner. This is documented by the filing of more than 530 international patent applications and granted patents, and by the publication of more than 75 articles in peer-reviewed scientific journals. She is co-founder and CEO of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing unique high-precision antibodies against various solid cancers. Furthermore, Özlem Türeci is an executive board member of the Association for Cancer Immunotherapy e.V. (CIMT). She was awarded the Vincenz Czerny Prize of the German Association for Hematology and Oncology and various other prizes and scholarships for her work.